Rigel drops asthma drug after mid-stage study fails
Aug 26 (Reuters) - Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed to improve the lung function of patients in a mid-stage trial.
The inhaled drug, R343, was being tested as a treatment for patients with allergic asthma.
While the drug was shown to be relatively safe and well tolerated, the trial failed to meet any of its goals, Rigel said.
The company said it will review its drug pipeline and will discuss its plans in the 'near-term.'
- Divided, Scots prepare to vote on fate of the United Kingdom |
- IPhone emerges from 'bygone era', reviewers hail bigger handset
- Fed renews zero rate pledge, but hints at steeper rate hike path |
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Islamic State campaign tests Obama's commitment to Mideast allies